Business
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference.\n\n \n \n \n \n \n \n\n \nPresentation details: Event: H.C. Wainwright 22nd Annual Global Investment Conference Date: Monday, September 14, 2020 Time: 11 a.m. EDT\nA live and archived webcast of the fireside chat can be accessed by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.\nAbout Protagonist Therapeutics, Inc.\nProtagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.\nProtagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com. \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-hc-wainwright-22nd-annual-global-investment-conference-301127980.html\nSOURCE Protagonist Therapeutics, Inc.","length":4083,"tagName":"div"}]